- Home
- CBUS vs QIPT Comparison
CBUS vs QIPT Comparison
Compare CBUS & QIPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBUS | QIPT |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.7M | 161.9M |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CBUS | QIPT |
|---|---|---|
| Price | $3.65 | $3.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $20.00 | $3.83 |
| AVG Volume (30 Days) | ★ 547.0K | 432.8K |
| Earning Date | 01-01-0001 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,262,000.00 | ★ $245,359,000.00 |
| Revenue This Year | N/A | $28.30 |
| Revenue Next Year | $99.13 | $1.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 134.56 | N/A |
| 52 Week Low | $1.09 | $1.37 |
| 52 Week High | $4.19 | $3.65 |
Technical Indicators
Market Signals| Indicator | CBUS | QIPT |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 71.36 |
| Support Level | $1.34 | $3.55 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.31 | 0.01 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 52.22 | 100.00 |
Price Performance
Historical ComparisonAbout CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp is a provider of durable medical equipment (DME) and home medical equipment (HME) in the United States. The Company specializes in delivering in-home treatments for the management of chronic conditions, with a primary focus on respiratory diseases, and supports patients with heart and pulmonary diseases, sleep apnea, reduced mobility, and other chronic health challenges. Its products and services include Sleep Apnea and PAP treatment, home medical equipment, home ventilation, and custom mobility solutions. The Company operates in a single business segment, comprising the sale and rental of medical equipment and related devices, and serves patients across 27 states in the United States.